Analyst Expectations For Neurocrine Biosciences’s Future
Latest Ratings for NBIX Date Firm Action From To Mar 2022 Piper Sandler Downgrades Overweight Neutral Feb 2022 Goldman Sachs Upgrades Neutral Buy Feb 2022 Morgan Stanley Maintains Equal-Weight View More Analyst Ratings for NBIX View the Latest Analyst Ratings read more